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THE VITAMIN D ANALOGUE BXL-628 ALTERS EXCITATION CONTRACTION COUPLING IN 
THE  ISOLATED BLADDER IN AGED WILDTYPE MICE DIFFERENTLY COMPARED TO 
BLADDERS FROM AGE-MATCHED TRANSGENIC ALZHEIMER’S DISEASE MICE 
 
Hypothesis / aims of study 
This is the first study to provide insights into the mechanisms involved in dysregulation of the urinary bladder in a transgenic 
model of Alzheimer’s disease (AD). AD is the most common neurodegenerative disorder and severely deteriorates patients’ 
quality of life. One of the most debilitating autonomic dysfunctions related to AD is urinary incontinence. Transgenic AD mice 
show besides behavioural characteristics of Alzheimer’s disease, altered micturition behaviour but also morphological changes 
within the bladder (1). In addition, altered contractile responses to KCl and muscarinic stimulation have been identified in an ex 
vivo setting (2). To identify novel potential treatment targets for patients suffering from AD and bladder dysfunctions, more 
mechanistic insights into the pathophysiology of bladder dysfunctions in AD patients are needed. Systemically, Vitamin D acts as 
an antioxidant and anti-inflammatory agent. On a bladder level, its inhibition of the RhoA/Rho kinase signalling pathway. reduction 
of calcium sensitisation leads to a higher threshold of muscarinic receptor stimulation. We therefore hypothesize that incubation 
with a Vitamin D3 analogue counteracts a potential misbalance of signalling systems within the dysfunctional AD. 
 
Study design, materials and methods 
Bladders and the proximal urethra from ten mice of the transgenic Alzheimer’s disease model APPswe/PS1ΔE9 and 10 wildtype 
(WT) , aged 91-93 weeks, were dissected, transurethrally catheterised and transferred to a heated organ bath (20 mL, 37 °C) 
containing continuously aerated Krebs’ solution. Subsequently, the bladder was filled to 90 μl with a filling rate of 0.2 ml/hour. 
After a resting period of 30 minutes, washing steps were performed, followed by a sequence of stimulations. Bladders were 
stimulated with electrical field stimulation (EFS) with muscle specific parameters (5 ms pulse duration, 6V, 8Hz), EFS with nerve 
specific parameters (24 V, 80 Hz), carbachol (1 μM) and KCl (100 mM) stimulation. Carbachol and KCl stimulations were 
terminated by washing steps. After a first sequence of all four stimulations, bladders were incubated for 10 minutes with the 
vitamin D3 analogue Bxl-628. During incubation with Bxl-628 a second sequence of stimulations, identical to the first sequence 
was given. 
 
Results 
Bladders originating from transgenic AD mice behaved differently to stimulation with KCl and EFS with nerve parameters 
compared to WT bladders: In bladders originating from transgenic AD mice, a decreased amplitude was recorded in response to 
KCl stimulation compared to WT mice. In addition, the time that was needed to reach the maximum of the initial peak of EFS 
evoked nerve stimulation was increased in AD mice compared to WT mice, after incubation with Bxl-628. 
Effects of incubation with the vitamin D3 analogue Bxl-628 were detected in both groups. However, these effects were not 
consistent between bladders originating from AD and WT mice. Incubation with the vitamin D3 analogue resulted in an increased 
amplitude of the KCl response in bladders of WT mice (Fig. 1). Furthermore, the time interval that was needed to reach the initial 
peak of the contractile responses was decreased after incubation with Bxl-628 for the KCl response in WT bladders.  The EFS 
response with muscle specific parameters in both, WT and AD bladders, and the EFS response with nerve specific parameters 
in WT bladders were also decreased (p=0.027, p=0.019 and p=0.002, respectively) . The time interval needed to reach the initial 
response was significantly increased after Bxl-628 and carbachol stimulation in AD bladders (p=0.048). 
 
 
Interpretation of results 
In control isolated bladder preparations, effects detected after the Vitamin D analogue Bxl-628  altered responses to excitatory 
pharmacological stimulation by increasing the amplitude of KCL stimulation and decreasing the time interval which was needed 
to reach the initial maximum of contractile responses to KCl, EFS muscle and nerve stimulation. However, in bladders of 
transgenic AD mice, the amplitudes after Bxl-628 did not change significantly and the time interval which was needed to reach 
the maximum of the initial peak was increased after carbachol stimulation but decreased after EFS muscle stimulation. Vitamin 
D3 exerts its effects by interaction with several signalling systems. Muscarinic activation by carbachol includes activation of L-
type calcium channels to induce contraction, as well as Rho kinase activation. The incubation with Bxl-628 and stimulation with 
different pharmacological agents may help to identify the changes in excitation coupling in AD. A counteracting effect in AD 
compared to WT bladders might even indicate a possible role of this agent in correcting a misbalance in excitation contraction 
coupling in AD bladders.   
 
Concluding message 
We identified a couple of signalling systems which might be of importance in bladder excitation contraction coupling associated 
with AD, such as the Rho A/Rho kinase system and calcium signalling in general. Future research should focus on identifying the 
role of potential amyloid-beta aggregation within the bladder wall to elucidate which interaction with specific proteins or ion-
channels takes place, thereby influencing bladder function. 
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